Pooled data from belimumab RCTs w/>3,000 pts evaluating kidney outcomes vs PLBO Tagging off BLISS-LN, pooled analysis w/marginal but real benefit to adding BEL in pts with SLE I offer this to all pts w/SLE LN on MMF, but I do not push it #ACRbest #ACR22 @RheumNow #0352 https://t.co/QYGgB3ue36

Consensus for #cancer screening in IIM Presented: When to Go Beyond Standard and Extended Screening #Plenary #ACR22 @rheumnow #myositis #ExpertOpinionNotData https://t.co/cL6zrMnzT3

Cancer screening in myositis: the path has always been unclear and inconsistent Workable consensus recommendations @Dr_Alex_Oldroyd risk stratification but still extensive investigation burden for most now need to look at effectiveness including cost ABST0002 #ACR22 @RheumNow https://t.co/322qnGjB9K

#ACR22 Abstr#0002 @Dr_Alex_Oldroyd presented eminence-based recommendation for patients with inflammatory myopathy. Enhanced screening for those high risk. Studies needed to assess feasibility i.e. cost, positive and negative predictive value of test etc. @RheumNow https://t.co/G1MyQDMhOa

Consensus for #cancer screening in IIM Presented: How Often to Screen #Plenary #ACR22 @rheumnow #myositis https://t.co/h1kp7Z9ynO

Consensus for #cancer screening in IIM Presented: What tests to order for screening #Plenary #ACR22 @rheumnow #myositis https://t.co/pPLcsFLtG9

Consensus for CA screening in IIM Presented: Risk factors to consider screening #Plenary #ACR22 @rheumnow #myositis https://t.co/CDNPaRUpPS

Risk stratification for cancer in myositis @RheumNow #ACR22 #Plenary https://t.co/j7R7P3PS7c

Some suggested screening tests for malignancy in myositis. Recommendations based on assessment of risk factors @RheumNow #ACR22 #Plenary https://t.co/B0eASeo8hG

Nice #SLE validation study. This kind of work is (1) time intensive and (2) thankless! It's not flashy but it winds up being the backbone/foundation for many subsequent studies Need more in other diseases, including sarcoidosis and myositis! @DidemSayginMD #ACR22 @RheumNow https://t.co/64z7DBFCnX

GUSTO 1y follow-up (TCZ +IVMPx3 but no ongoing PNL in new GCA): initial 24w results disappointing (permanent visual loss x1) BUT follow-up at 2y: control overwhelmingly maintained in responders We need to keep asking: can we use less PNL in GCA? When? ABST0470 #ACR22 @RheumNow https://t.co/smyw2nykO5 https://t.co/d2at0pJlSB

• https://twitter.com/drdavidliew/status/1325906973540315136

Xeljanz in PsA (@pfizer funded) #ACR22 @RheumNow ⚠️safety data -Pancytopenia -Transaminitis -Dyslipidemia -Elevated CPK without #myositis -Avoid in pregnancy and GI strictures 🤰Stop JAKi at least one month prior to conception🤰

#ACR22 Plenary 1. Abstr#0001 Another important use of #methotrexate. MIRROR RCT showed greater response in pegloticase + MTX vs pegloticase + PBO and lower infusion reaction. Be interesting to define MTX dose and ?other DMARDs esp in patients with CKD @RheumNow #ACRBest https://t.co/xkP6ZZGQfu

Abst#0001 MIRROR RCT at #ACR22 #plenary Pts with gout on #pegloticase and #gout sustained higher urate lowering response in pts cotreated with #MTX benefit beyond 6 months @rheumnow https://t.co/rTZ3fPaFJS

Xeljanz use in AS #ACR22 (@pfizer sponsored) @RheumNow -Included patients with at least bilateral grade 2 SI or grade 3/4 unilateral SI -5mg BID Xeljanz -Significantly more patients had ASAS20/40 response, CRP reduction, & QOL, vs. placebo -Onset of action noticed at 2 weeks https://t.co/DisKpgR0pt